NR4A1 and neoplasm: Analysis of the subgroup that comprised only patients with hormone receptor-positive tumours (45%) in the TARGET trial showed a similar separation of the Kaplan–Meier curves to that seen in the overall population in the North American trial (in which 89% of patients had hormone receptor-positive tumours).